AR052544A1 - DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT - Google Patents
DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING ITInfo
- Publication number
- AR052544A1 AR052544A1 ARP050105485A ARP050105485A AR052544A1 AR 052544 A1 AR052544 A1 AR 052544A1 AR P050105485 A ARP050105485 A AR P050105485A AR P050105485 A ARP050105485 A AR P050105485A AR 052544 A1 AR052544 A1 AR 052544A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- heteroaryl
- independently
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso de los compuestos de la formula general A para el tratamiento de diversas enfermedades, así como a la preparacion de compuestos de la formula general A. Reivindicacion 1: Derivado de quinolina de la formula general A en donde A está seleccionado del grupo que comprende -arilo C6-12, - heteroarilo C5-18, -cicloalquilo C3-12 y -heterocicloalquilo C3-12; R1 y R2 son iguales o diferentes y están seleccionados, una o varias veces independientemente entre sí, del grupo que comprende H, hidroxi, halogeno, nitro, ciano, -alquilo C1-6, -hidroxi-alquilo C1-4, - alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, heterocicloalquilo C3-12, -arilo C6-12, -heteroarilo C5-18, -alcoxi C1-6, -alcoxi c1-6- alcoxi c1-6, -alcoxi C1-6-alquilo C1-6, -alcoxi C1-6-alcoxi C1-6-alquilo C1-6, -(CH2)n-arilo C6-12, -(CH2)n-heteroarilo C5-18, -(CH2)n- cicloalquilo C3-10, -(CH2)n-heterocicloalquilo C3-12, -fenilen-(CH2)p-R6, -(CH2)pPO3(R6)2, -(CH2)p-NR4S(O)R5, -(CH2)p-NR4S(O)2R5, -(CH2)p- NR4CONR5R6, -(CH2)p-NR4COOR5, -(CH2)p-NR4C(NH)NR5R6, -(CH2)p-NR4CSNR5R6, -(CH2)p-NR4S(O)NR5R6, -(CH2)p- NR4S(O)23NR5R6, -(CH2)p-COR5, -(CH2)p-CSR5, -(CH2)p-S(O)R5, -(CH2)p-S(O)(NH)R5, -(CH2)p-S(O)2R5, -(CH2)p-S(O)2NR5R6, -(CH2)p-SO2OR5, -(CH2)p- CO2R5, -(CH2)p-CONR5R6, -(CH2)p-CSNR5R6, -OR5, -(CH2)p-SR5 y -CR5(OH)-R6, en donde -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -heterocicloalquilo C3-12, -arilo C6-12, -heteroarilo C5-18 y/o -alcoxi c1-6 no están sustituidos o están sustituidos, una o varias veces independientemente entre sí, con hidroxi, halogeno, nitro, ciano, fenilo, -NR5R6, alquilo y/u -OR5, en donde la estructura del C del -cicloalquilo C3-10 y del -alquilo C1-10 puede contener, una o varias veces independientemente entre sí, átomos de N, O, S y/o grupos C=O y/o uno o varios enlaces dobles, y/o R1 y R2 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o -NR4; X, Y, Z, son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende -CR3=, -CR3R4-, -C(O)-, -N=, -S-, -O-, -NR3-, -S(O)2-, -S(O)- y -S(O)NH-, y se hallan entre X, Y y Z enlaces simples o dobles; R3 es H, -alquilo C1-10 o -alcanoílo C1-10; R4 es H o -alquilo C1-10; R5 y R6 son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende H, -alquilo C1-10, -alquenilo C2-10, - alquinilo C2-10, -alcoxi C1-6, -cicloalquilo C3-10, -heterocicloalquilo C3-12, -arilo C6-12 y -heteroarilo C5-18, en donde -alquilo C1-10, -alquenilo C2-10, -alquinilo C2-10, -alcoxi C1-6, -cicloalquilo C3-10, - heterocicloalquilo C3-12, -arilo C6- 12 y/o -heteroarilo C5-18 no están sustituidos o están mono- o polisustituidos independientemente entre sí con hidroxi, halogeno, ciano, nitro, -OR7, -NR7R8, -C(O)NR7R8, -C(O)OR7 y/o -alquilo C1-6, en donde -alquilo c1-6 no está sustituido o está mono- o polisustituido independientemente entre sí con halogeno, hidroxi, ciano, -NR7R8, -OR7 y/o fenilo; y/o R5 y R6 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o NR4; R7, R8 son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende H, -alquilo c1-4, -arilo C6-12 y -heteroarilo C5-18, en donde alquilo, arilo, heteroarilo no está sustituido o está sustituido, una o varias veces independientemente entre sí, con y/o alcoxi, o R7 y R8 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o - NR4;m', mö = independientemente entre sí 0-4; n = 1-6, p = 0-6, así como sus N-oxidos, solvatos, hidratos, estereoisomeros, diastereoisomeros, enantiomeros y sales con la condicion de que, cuando X, Y, Z significan independientemente entre sí 1, 2 o 3 N, 1) el esqueleto del subgrupo X-Y-Z no sea N- CH-N, CH-N-N o -N-N-N y 2) X no sea NH cuando Y y Z son al mismo tiempo CH.Use of the compounds of the general formula A for the treatment of various diseases, as well as the preparation of compounds of the general formula A. Claim 1: Quinoline derivative of the general formula A wherein A is selected from the group comprising - C6-12 aryl, - C5-18 heteroaryl, - C3-12 cycloalkyl and - C3-12 heterocycloalkyl; R1 and R2 are the same or different and are selected, once or several times independently from each other, from the group comprising H, hydroxy, halogen, nitro, cyano, -C 1-6 alkyl, -hydroxy-C 1-4 alkyl, - C 2 alkenyl -6, -C2-6alkynyl, -C3-10cycloalkyl, C3-12 heterocycloalkyl, -C6-12 -aryl, -C5-18 heteroaryl, -C1-6 alkoxy, -C1-6 alkoxy-C1-6 alkoxy, - C1-6 alkoxy-C1-6 alkyl, -C 1-6 alkoxy-C1-6 alkoxy-C1-6 alkyl, - (CH2) n-aryl C6-12, - (CH2) n-heteroaryl C5-18, - ( CH2) n- C3-10 cycloalkyl, - (CH2) n-heterocycloalkyl C3-12, -phenylene- (CH2) p-R6, - (CH2) pPO3 (R6) 2, - (CH2) p-NR4S (O) R5, - (CH2) p-NR4S (O) 2R5, - (CH2) p- NR4CONR5R6, - (CH2) p-NR4COOR5, - (CH2) p-NR4C (NH) NR5R6, - (CH2) p-NR4CSNR5R6, - (CH2) p-NR4S (O) NR5R6, - (CH2) p- NR4S (O) 23NR5R6, - (CH2) p-COR5, - (CH2) p-CSR5, - (CH2) pS (O) R5, - (CH2) pS (O) (NH) R5, - (CH2) pS (O) 2R5, - (CH2) pS (O) 2NR5R6, - (CH2) p-SO2OR5, - (CH2) p- CO2R5, - (CH2) p-CONR5R6, - (CH2) p-CSNR5R6, -OR5, - (CH2) p-SR5 and -CR5 (OH) -R6, where -C1-6 alkyl, -C2-6 alkenyl, -alkynyl C2-6, -C3-10 cycloalkyl, -C3-12 heterocycloalkyl, -C6-12 -aryl, -C5-18 heteroaryl and / or -C1-6 alkoxy are not substituted or substituted, once or several times independently of each other, with hydroxy, halogen , nitro, cyano, phenyl, -NR5R6, alkyl and / or -OR5, wherein the C structure of the C3-10 cycloalkyl and the C1-10 alkyl can contain, once or several times independently of each other, N atoms , O, S and / or groups C = O and / or one or several double bonds, and / or R1 and R2 optionally form a bridge of 3-10 methylene units, where up to two methylene units are optionally replaced with O, S and / or -NR4; X, Y, Z, are the same or different and are independently selected from the group comprising -CR3 =, -CR3R4-, -C (O) -, -N =, -S-, -O-, - NR3-, -S (O) 2-, -S (O) - and -S (O) NH-, and single or double bonds are between X, Y and Z; R3 is H, -C1-10 alkyl or -C1-10 alkanoyl; R4 is H or -C1-10 alkyl; R5 and R6 are the same or different and are independently selected from the group comprising H, -C1-10 alkyl, -C2-10 alkenyl, -C2-10 alkynyl, -C1-6 alkoxy, -C3-10 -cycloalkyl , -C3-12 heterocycloalkyl, -C6-12 -aryl and -C5-18 heteroaryl, wherein -C1-10 alkyl, -C2-10 alkenyl, -C2-10 alkynyl, -C1-6 alkoxy, -C3-10 -cycloalkyl , - C3-12 heterocycloalkyl, C6-12 -aryl and / or -C5-18 heteroaryl are not substituted or are mono- or polysubstituted independently of each other with hydroxy, halogen, cyano, nitro, -OR7, -NR7R8, -C ( O) NR7R8, -C (O) OR7 and / or -C1-6 alkyl, wherein -C1-6 alkyl is not substituted or is mono- or polysubstituted independently of one another with halogen, hydroxy, cyano, -NR7R8, -OR7 and / or phenyl; and / or R5 and R6 optionally form a bridge of 3-10 methylene units with each other, where up to two methylene units are optionally replaced with O, S and / or NR4; R7, R8 are the same or different and are independently selected from the group comprising H, -C1-4 alkyl, -C6-12 alkyl and -C5-18 heteroaryl, wherein alkyl, aryl, heteroaryl is unsubstituted or is substituted, once or several times independently of each other, with and / or alkoxy, or R7 and R8 optionally form a bridge of 3-10 methylene units, where up to two methylene units are optionally replaced with O, S and / o - NR4; m ', mö = independently from each other 0-4; n = 1-6, p = 0-6, as well as their N-oxides, solvates, hydrates, stereoisomers, diastereoisomers, enantiomers and salts with the proviso that, when X, Y, Z independently mean each other 1, 2 or 3 N, 1) the skeleton of subgroup XYZ is not N-CH-N, CH-NN or -NNN and 2) X is not NH when Y and Z are at the same time CH.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004063223A DE102004063223A1 (en) | 2004-12-22 | 2004-12-22 | New quinoline derivatives are ephrin receptor kinase inhibitors useful for the treatment of e.g. blood vessels diseases, hyperproliferations, chronic or acute neurodegenerative diseases, psoriasis, eczema and scleroderma |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052544A1 true AR052544A1 (en) | 2007-03-21 |
Family
ID=36599298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105485A AR052544A1 (en) | 2004-12-22 | 2005-12-22 | DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT |
Country Status (7)
Country | Link |
---|---|
CN (1) | CN101087788A (en) |
AR (1) | AR052544A1 (en) |
DE (1) | DE102004063223A1 (en) |
GT (1) | GT200500381A (en) |
PA (1) | PA8657701A1 (en) |
SV (1) | SV2007002357A (en) |
UY (1) | UY29308A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103382206B (en) * | 2012-05-04 | 2016-09-28 | 上海恒瑞医药有限公司 | Quinoline or quinazoline derivative, its preparation method and in application pharmaceutically |
CN106565823B (en) * | 2016-11-10 | 2020-09-11 | 珠海诺贝尔国际生物医药研究院有限公司 | Eph receptor small molecule inhibitor and preparation method thereof |
WO2019233458A1 (en) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Vegfr inhibitor, preparation method therefor and use thereof |
CN110577546B (en) * | 2018-06-08 | 2021-09-07 | 江苏威凯尔医药科技有限公司 | VEGFR inhibitor and preparation method and application thereof |
CN113061142B (en) * | 2020-01-02 | 2024-08-27 | 爱科诺生物医药(香港)有限公司 | Heterocyclic compound with activity of inhibiting programmed cell necrosis pathway and application thereof |
CN113150009B (en) * | 2020-01-07 | 2023-05-23 | 爱科诺生物医药(香港)有限公司 | Heterocyclic compound with activity of inhibiting programmed cell necrosis pathway and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3919238A (en) * | 1973-06-06 | 1975-11-11 | Morton Norwich Products Inc | 9-(Substituted amino)imidazo(4,5-f) quinolines |
CA1263378A (en) * | 1985-01-08 | 1989-11-28 | Robert James Alaimo | Imidazo¬4,5-f|quinolines useful as immunomodulating agents |
WO1993003030A1 (en) * | 1991-08-02 | 1993-02-18 | Pfizer Inc. | Quinoline derivatives as immunostimulants |
-
2004
- 2004-12-22 DE DE102004063223A patent/DE102004063223A1/en not_active Ceased
-
2005
- 2005-12-19 CN CNA2005800444603A patent/CN101087788A/en active Pending
- 2005-12-21 GT GT200500381A patent/GT200500381A/en unknown
- 2005-12-22 AR ARP050105485A patent/AR052544A1/en not_active Application Discontinuation
- 2005-12-22 SV SV2005002357A patent/SV2007002357A/en not_active Application Discontinuation
- 2005-12-22 UY UY29308A patent/UY29308A1/en not_active Application Discontinuation
- 2005-12-22 PA PA20058657701A patent/PA8657701A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
GT200500381A (en) | 2006-08-03 |
PA8657701A1 (en) | 2006-09-08 |
UY29308A1 (en) | 2006-06-30 |
CN101087788A (en) | 2007-12-12 |
SV2007002357A (en) | 2007-02-16 |
DE102004063223A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180462A1 (en) | TOC MODULATORS AND METHODS OF USING THEM | |
PE20021010A1 (en) | SPIROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE-7 INHIBITORS | |
ECSP088590A (en) | MULTICYCLIC AMINO ACID DERIVATIVES AND THEIR METHODS OF USE | |
PE20142456A1 (en) | OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks | |
AR052544A1 (en) | DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT | |
AR078786A1 (en) | CHROMENONE DERIVATIVES | |
AR044078A1 (en) | SUBSTITUTED DIHYDROQUINAZOLINS | |
CO5680439A2 (en) | CYCLOTIOCARBAMATE DERIVATIVES AS PR MODULATORS AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | |
DE602006006850D1 (en) | AZABICYCLO (3,1,0) -HEXAN DERIVATIVES SUITABLE AS MODULATORS OF DOPAMINE D3 RECEPTORS | |
UY29469A1 (en) | SULFOXIMINO-MACROCYCLIC COMPOUNDS AND THEIR SALTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PREPARATION METHODS AND USES OF THE SAME. | |
AR034261A1 (en) | COMPOUNDS DERIVED FROM PIRAZOL [1,5-A] PIRIDINE; PHARMACEUTICAL COMPOSITIONS, ITS USE IN THE MANUFACTURE OF MEDICINES, AND METHODS OF TREATMENT OF DISEASES MEDIATED BY KINASES | |
AR041347A1 (en) | IMIDAZOL DERIVATIVES [1,2-A] PIRAZINAS AS INHIBITORS OF CYCLINE DEPENDENT KINASES | |
AR054035A1 (en) | BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USE OF THE SAME | |
AR050617A1 (en) | SULFONAMID PYRIMIDIN DERIVATIVES AS CHEMIOKIN RECEPTORS MODULATORS | |
AR058703A1 (en) | THYROSINKINASE INHIBITING TRIAZOLOPIRIDAZINS, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THERAPEUTIC AND USES IN THE TREATMENT OF CANCER | |
AR072906A1 (en) | MODIFIED NUCLEOSIDS USEFUL AS ANTIVIRAL | |
AR072791A1 (en) | DERIVATIVES OF TIAZOLIDIN-2, 4-DIONA, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER. | |
AR040806A1 (en) | DERIVATIVES OF PIPERIDI-2-ONA 1.6 DISUSTITUTED, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND TREATMENT METHOD | |
AR080785A1 (en) | DERIVATIVES OF IMIDAZO [1,2-A] PYRIMIDINE, PROCESS TO PREPARE THEM AND INTERMEDIARIES OF SUCH SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THEM IN THE TREATMENT OF PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM, SUCH AS PARK AND OTHERS. | |
AR056511A1 (en) | DERIVATIVES OF 2-AMINOPIRIMIDINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HISTAMINE RECEIVER H4 | |
AR085406A1 (en) | N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTERIDINONES | |
AR045388A1 (en) | INHIBITORS OF THE N3-SUBSTITUTED IMIDAZOPIRIDINIC C-KIT | |
AR048028A1 (en) | 5,6-DIALQUIL-7-AMINO-TRIAZOLOPIRIMIDINAS, PROCEDURES FOR THEIR PREPARATION AND THE USE OF THE SAME TO COMBAT HARMFUL FUNGES, AS WELL AS PRODUCTS CONTAINING THEM | |
MA39707B1 (en) | Derivatives of 1,2-dihydro-3h-pyrrolo [1,2-c] imidazol-3-one and their use as antibacterial agents | |
UY29070A1 (en) | FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |